Abcuro
MA - NewtonBiotechnology
Focus: Abcuro is a public biotechnology company focused on T cell therapy and antibody-based treatments for gene and cell therapy indications. Founded in 2004 and headquartered in Newton, MA, the company operates at a mid-cap biotech scale with a specialized therapeutic focus.
Profile data last refreshed 23h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Abcuro
AI assessmentNot HiringNo open roles listed right now. Follow Abcuro to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 1/2
Clinical Trials (3)
NCT06450886Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
Phase 2/3Help build intelligence for Abcuro
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.